
Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.
Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.
The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.
The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.
The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.
Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.
Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.
Patients administered 75 mg or higher of olpasiran every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36.
Evolocumab found to reduce reduced adverse cardiovascular events in combination with statin therapy compared to placebo plus statin therapy.
The American Heart Association issued a dietary guidance in 2021 suggesting that adults consume a variety of fruits and vegetables, choose whole grains instead of refined grains, eat healthy protein sources and lean cuts of meat, and substitute nonfat and low-fat dairy products for full-fat versions, among other measures.
In 2020, heart disease death rates increased in adults across all age, sex, racial and ethnic groups, specifically among younger adults and non-Hispanic Black adults.
However, findings do not preclude the possibility that mechanisms other than cardiac remodeling may be responsible for benefits of SGLT2 inhibition.
Approximately 10% of patients in trial experienced a heart attack, stroke, blocked arteries requiring treatment, or death from cardiovascular disease.
Intravenous iron reduced the risk of hospitalization for heart failure or cardiovascular death by approximately 20%.
Chlorthalidone was associated with more individuals with potassium levels below 3.1 mmol/L, suggesting a greater risk of hypokalemia.
Experts said the results will likely not alter practice and clinicians will likely continue to use torsemide.
In addition to the ongoing COVID-19 pandemic, significant public health concerns include opioid overdoses, maternal mortality disparities, and climate change.
FDA Commissioner Robert Califf said that misinformation is the most common cause of death in the United States.
Among nicotine users, there was an approximately 4 beat per minute jump in heart rate after vaping or smoking.
Results of a recent study confirmed that patients already taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) should not discontinue taking them due to COVID-19 infection.
For patients with COVID-19, the combination of the disease and preexisting atrial arrhythmias may create a pathologic synergy that significantly increases the risk for major adverse cardiac events and death.
The researchers examined the health records of more than 1100 adults, who had an average age of 45 years, were 52% female, and who are participants in the ongoing Childhood Determinants of Adult Health study.
Green spaces were also associated with an improvement in air quality.
Centhaquine was found to improve survival in those with hypovolemic shock.
A majority of young adults with cardiovascular disease are not receiving the annual influenza vaccine despite their heightened risk of secondary infections.
Researchers analyzed the survey responses of more than 1400 current users of e-cigarette and related products from 18 to 64 years of age, evenly divided among male and female, who took part in a national online survey in 2016.
Cannabis use is becoming much more prevalent in the United States, as several more states have recently legalized it for recreational or medicinal use.
The COVID-19 pandemic has forced many cardiovascular rehabilitation programs to go virtual.